Hayes-Jordan AA, et al. - In this phase 2 clinical trial, researchers assessed cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (CRS-HIPEC) with cisplatin for desmoplastic small round cell tumor (DSRCT) and pediatric-type abdominal sarcomas. Findings demonstrated that in select DSRCT patients, complete CRS-HIPEC with cisplatin was effective. Poorer outcomes were reported in DSRCT patients with hepatic or portal metastasis.

• Including a total of 20 patients who underwent CRS-HIPEC procedures with cisplatin from 2012 to 2013, a prospective cohort study was carried out.
• Researchers enrolled all patients in phase 2 clinical trial.
• They excluded patients with extraabdominal disease and in whom complete cytoreduction (CCR0–1) could not be achieved.
• They recorded all outcomes.

• DSRCT was detected in 14 patients, while 5 patients had other sarcomas.
• As per data, one patient had repeat HIPEC.
• Findings demonstrated that median overall survival after surgery was significantly longer in patients with DSRCT, compared with patients with other tumors (44.3 vs 12.5 months, p=0.0013).
• For DSRCT patients, the 3-year overall survival from time of diagnosis was 79 %.
• Estimated median recurrence-free survival (RFS) was 14.0 months.
• However, researchers noted that RFS for patients with DSRCT was significantly longer than for non-DSRCT patients (14.9 vs 4.5 months, p=0.0012).
• Results also revealed longer median RFS in those without hepatic or portal metastases vs those with tumors at these sites (37.9 vs 14.3 months, p=0.02), among DSRCT patients.
• In addition, findings demonstrated in 100 % of patients without hepatic or portal metastasis, there was no peritoneal disease recurrence after CRS-HIPEC.